Overview

HF Patients With LAVDs Being Treated With SGLT2i

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure patients with left ventricular assist devices (LVAD).
Phase:
Phase 4
Details
Lead Sponsor:
University of Chicago